RxDoctor Payments DataLook up a doctor →

Ronald South, MD

Neurology · Jonesboro, ARNPI 1457314577

Payments from drug & device makers

$58,877in general payments, 2019–2025

Across 958 payments — averaging $61.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$45K
  • Novartis$2K
  • AbbVie$1K
  • UCB, Inc.$783
  • MDD US Operations, LLC$781
  • Amgen$686
  • plus $9K from 45 others

What the payments were for

  • Consulting fees$11,49020%
  • Speaking & faculty fees$27,70347%
  • Travel & lodging$4,3607%
  • Food & beverage$15,23526%
  • Education$900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,877 in reported general payments places this provider in the 85th percentile of 93 neurology providers in Arkansas.

See all neurology providers in Arkansas

Medicare billing

Part B allowed, 2024
$86,310
Medicare patients
406
Services billed
842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab21$218,925
VumerityDiroximel Fumarate14$120,281
Gamunex-CImmune Globul G/Gly/Iga Avg 4630$119,838
IngrezzaValbenazine Tosylate13$113,547
RytaryCarbidopa/Levodopa88$95,599
Nurtec OdtRimegepant Sulfate60$87,320
Teriflunomide27$80,899
QuliptaAtogepant63$65,367
UbrelvyUbrogepant32$48,072
Aimovig AutoinjectorErenumab-Aooe32$38,533
Emgality PenGalcanezumab-Gnlm25$18,683
Ajovy SyringeFremanezumab-Vfrm15$17,579
XcopriCenobamate14$16,071
Pregabalin194$6,914
Memantine Hcl ErMemantine Hcl90$5,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$541$120,28114 claims
Neurocrine Biosciences, Inc.Ingrezza$614$113,54713 claims
AbbVieQulipta, Ubrelvy$1,234$113,43995 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$428$97,574120 claims
PfizerNurtec Odt$467$87,32060 claims
SK Life Science, Inc.Xcopri$382$16,07114 claims
Upsher-smith Laboratories LLCTopiramate$189$84571 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 93 neurology providers in Arkansas.

Other neurology in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →